文献速递淋巴瘤MDS 与骨髓增殖性肿瘤

CD19靶向CAR-T细胞治疗后长期缓解的B细胞淋巴瘤患者中髓系肿瘤风险随时间升高

Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time?
PubMed 文献 · Leukemia · 2025-04-24

该回顾性研究分析了4个法国中心539例接受CD19靶向CAR-T细胞治疗的B细胞淋巴瘤患者,中位随访25个月时t-MN的2年累积发生率为4.5%,以t-MDS(62%)和t-AML(38%)为主且高危细胞遗传学常见,t-MN诊断后中位总生存仅4.5个月,MCV和ICANS分级为关键风险因素。

要点

  • 中位随访25个月,t-MN的2年累积发生率为4.5%。
  • t-MN以t-MDS(62%)和t-AML(38%)为主,高危细胞遗传学常见。
  • t-MN诊断后中位总生存为4.5个月。

核心结论

  • 本研究强调t-MN是CAR-T细胞治疗的严重晚期并发症。
  • MCV和ICANS分级被确定为关键风险因素。

研究设计与样本

  • 回顾性分析4个法国中心539例接受CD19靶向CAR-T细胞治疗的B细胞淋巴瘤患者。
  • 采用竞争风险模型估计t-MN累积发生率,以复发或死亡为竞争风险。
  • 采用单因素分析和倾向性评分匹配(PSM)分析评估风险因素,年龄和既往治疗线数为协变量。

主要发现

  • 中位随访25个月,t-MN的2年累积发生率为4.5%。
  • t-MN主要类型为t-MDS(62%)和t-AML(38%),高危细胞遗传学常见。
  • t-MN诊断后中位总生存为4.5个月。
  • 单因素分析中,年龄较大(p < 0.01)、MCV较高(p < 0.01)和ICANS分级较高(p = 0.04)与t-MN风险增加相关。
  • PSM后,MCV和ICANS分级仍为显著风险因素;含CD28共刺激域的CAR-T产品有t-MN风险升高趋势(p = 0.09)。

关键数值与推荐

  • t-MN的2年累积发生率为4.5%。
  • t-MN中t-MDS占62%,t-AML占38%。
  • t-MN诊断后中位总生存为4.5个月。
  • 单因素分析:年龄较大p < 0.01,MCV较高p < 0.01,ICANS分级较高p = 0.04。
  • 含CD28共刺激域的CAR-T产品t-MN风险趋势p = 0.09。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapy-related myeloid neoplasms (t-MN), including myelodysplastic neoplasms (t-MDS) and acute myeloid leukemia (t-AML), have emerged as significant late complications after CAR T cell therapy. We retrospectively analyzed 539 patients with B cell lymphoma treated with CD19 directed CAR T cell therapy across four French centers. Cumulative incidences of t-MN was estimated with relapse or death treated as competing risk. Univariate and propensity score matching (PSM) analyses were conducted to assess risk factors with age and the number of prior treatments as covariates. After a median follow-up of 25 months, the cumulative incidence of t-MN was 4.5% at 2 years. T-MN occurred predominantly as t-MDS (62%) and t-AML (38%) with high cytogenetic risk. Median overall survival after t-MN diagnosis was 4.5 months. In univariate analysis, older age (p < 0.01), higher MCV (p < 0.01), and higher ICANS grade (p = 0.04) were associated with increased risk of t-MN. After PSM, MCV and ICANS grade remained significant risk factors. CAR T cell products with CD28 co-stimulatory domains trended towards higher t-MN risk (p = 0.09). NGS analysis showed that 85.7% of t-MN had pre-existing mutations, most commonly TP53. This study highlights t-MN as a severe late complication of CAR T cell therapy. MCV and ICANS grade were identified as key risk factors.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Gazeau N, Beauvais D, Tilmont R, et al. Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? Leukemia. 2025. PMID: 40275069. doi:10.1038/s41375-025-02605-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。